232 related articles for article (PubMed ID: 18240293)
1. Shaken, not stirred: mechanical stress testing of an IgG1 antibody.
Kiese S; Papppenberger A; Friess W; Mahler HC
J Pharm Sci; 2008 Oct; 97(10):4347-66. PubMed ID: 18240293
[TBL] [Abstract][Full Text] [Related]
2. Induction and analysis of aggregates in a liquid IgG1-antibody formulation.
Mahler HC; Müller R; Friess W; Delille A; Matheus S
Eur J Pharm Biopharm; 2005 Apr; 59(3):407-17. PubMed ID: 15760721
[TBL] [Abstract][Full Text] [Related]
3. Equilibrium studies of protein aggregates and homogeneous nucleation in protein formulation.
Kiese S; Pappenberger A; Friess W; Mahler HC
J Pharm Sci; 2010 Feb; 99(2):632-44. PubMed ID: 19548315
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a dual-wavelength size exclusion HPLC method with improved sensitivity to detect protein aggregates and its use to better characterize degradation pathways of an IgG1 monoclonal antibody.
Bond MD; Panek ME; Zhang Z; Wang D; Mehndiratta P; Zhao H; Gunton K; Ni A; Nedved ML; Burman S; Volkin DB
J Pharm Sci; 2010 Jun; 99(6):2582-97. PubMed ID: 20039394
[TBL] [Abstract][Full Text] [Related]
5. Product and process understanding to relate the effect of freezing method on glycation and aggregation of lyophilized monoclonal antibody formulations.
Awotwe-Otoo D; Agarabi C; Read EK; Lute S; Brorson KA; Khan MA
Int J Pharm; 2015 Jul; 490(1-2):341-50. PubMed ID: 25835267
[TBL] [Abstract][Full Text] [Related]
6. Mechanically-induced aggregation of the monoclonal antibody cetuximab.
Lahlou A; Blanchet B; Carvalho M; Paul M; Astier A
Ann Pharm Fr; 2009 Sep; 67(5):340-52. PubMed ID: 19695370
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the physical stability of a lyophilized IgG1 mAb after accelerated shipping-like stress.
Telikepalli S; Kumru OS; Kim JH; Joshi SB; O'Berry KB; Blake-Haskins AW; Perkins MD; Middaugh CR; Volkin DB
J Pharm Sci; 2015 Feb; 104(2):495-507. PubMed ID: 25522000
[TBL] [Abstract][Full Text] [Related]
8. Synergistic Effect of Cavitation and Agitation on Protein Aggregation.
Torisu T; Maruno T; Hamaji Y; Ohkubo T; Uchiyama S
J Pharm Sci; 2017 Feb; 106(2):521-529. PubMed ID: 27887723
[TBL] [Abstract][Full Text] [Related]
9. Relevant shaking stress conditions for antibody preformulation development.
Eppler A; Weigandt M; Hanefeld A; Bunjes H
Eur J Pharm Biopharm; 2010 Feb; 74(2):139-47. PubMed ID: 19922795
[TBL] [Abstract][Full Text] [Related]
10. Nonnative aggregation of an IgG1 antibody in acidic conditions, part 2: nucleation and growth kinetics with competing growth mechanisms.
Brummitt RK; Nesta DP; Chang L; Kroetsch AM; Roberts CJ
J Pharm Sci; 2011 Jun; 100(6):2104-19. PubMed ID: 21213307
[TBL] [Abstract][Full Text] [Related]
11. [Determination of the particle size and relative light scattering intensity of aggregates of human IgG and humanized monoclonal antibody product induced by various stress using dynamic light scattering].
Niimi S
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2011; (129):55-60. PubMed ID: 22259843
[TBL] [Abstract][Full Text] [Related]
12. Surface activity of a monoclonal antibody.
Mahler HC; Senner F; Maeder K; Mueller R
J Pharm Sci; 2009 Dec; 98(12):4525-33. PubMed ID: 19655376
[TBL] [Abstract][Full Text] [Related]
13. The missing piece in the puzzle: Prediction of aggregation via the protein-protein interaction parameter A
Koepf E; Schroeder R; Brezesinski G; Friess W
Eur J Pharm Biopharm; 2018 Jul; 128():200-209. PubMed ID: 29723667
[TBL] [Abstract][Full Text] [Related]
14. Conformational analysis of protein secondary structure during spray-drying of antibody/mannitol formulations.
Schüle S; Friess W; Bechtold-Peters K; Garidel P
Eur J Pharm Biopharm; 2007 Jan; 65(1):1-9. PubMed ID: 17034996
[TBL] [Abstract][Full Text] [Related]
15. Development of a microflow digital imaging assay to characterize protein particulates during storage of a high concentration IgG1 monoclonal antibody formulation.
Wuchner K; Büchler J; Spycher R; Dalmonte P; Volkin DB
J Pharm Sci; 2010 Aug; 99(8):3343-61. PubMed ID: 20229596
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of agitation-induced aggregation of an IgG-antibody by hydroxypropyl-beta-cyclodextrin.
Serno T; Carpenter JF; Randolph TW; Winter G
J Pharm Sci; 2010 Mar; 99(3):1193-206. PubMed ID: 19774651
[TBL] [Abstract][Full Text] [Related]
17. Aggregation and pH-temperature phase behavior for aggregates of an IgG2 antibody.
Sahin E; Weiss WF; Kroetsch AM; King KR; Kessler RK; Das TK; Roberts CJ
J Pharm Sci; 2012 May; 101(5):1678-87. PubMed ID: 22246657
[TBL] [Abstract][Full Text] [Related]
18. Thermally induced degradation pathways of three different antibody-based drug development candidates.
Fincke A; Winter J; Bunte T; Olbrich C
Eur J Pharm Sci; 2014 Oct; 62():148-60. PubMed ID: 24878389
[TBL] [Abstract][Full Text] [Related]
19. Influence of hydroxypropyl-Beta-cyclodextrin on the stability of dilute and highly concentrated immunoglobulin g formulations.
Härtl E; Winter G; Besheer A
J Pharm Sci; 2013 Nov; 102(11):4121-31. PubMed ID: 24105716
[TBL] [Abstract][Full Text] [Related]
20. The impact of thermal treatment on the stability of freeze-dried amorphous pharmaceuticals: II. Aggregation in an IgG1 fusion protein.
Wang B; Cicerone MT; Aso Y; Pikal MJ
J Pharm Sci; 2010 Feb; 99(2):683-700. PubMed ID: 19798764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
